Immunogenicity to herpes zoster recombinant subunit vaccine in immune-mediated rheumatic patients under treatment with JAK inhibitors
Our study provides valuable insights into the immune responses elicited by the recombinant inactive vaccine in patients with IMRDs treated with JAK-i. In these patients we have observed a broad impact on the adaptive humoral and cellular immune responses, suggesting a potential reduction in protection against HZ infection and VZV reactivation.
Authors
- C. Sieiro Santos (ORCID: https://orcid.org/0000-0003-0889-9877)
- Juan García Herrero
- Ana M. Sahagún (ORCID: https://orcid.org/0000-0003-3311-4226)
- Jose G Ruiz de Morales (ORCID: https://orcid.org/0000-0002-0291-4071)
- Estefanía Robles Martín
- A. López Robles
- José Ordás Martínez
- C. Álvarez Castro (ORCID: https://orcid.org/0000-0001-8156-4470)
- Ronald Colindres
Institutions
- Complejo Asistencial Universitario de Palencia (ES)
- Universidad de León (ES)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1093/rheumatology/keae584
- Citations
- 9
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.48
Funders
- European League Against Rheumatism